Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTBF Conditioning for Allo-HSCT in R/R AML
NCT06385808Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
01
Overview
Open-label, single-arm trial of mitoxantrone in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Recurrence rate at 2 years. Planned start May 2024; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06385808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385808.